Pyelonephritis, Kidney Transplant recipients
Conditions
Brief summary
Clinical cure and no additional antibiotic treatment since the end of antibiotic treatment up to the main evaluation at day 30. Clinical cure is defined as fever <38°C and no symptoms of UTI.
Detailed description
Clinical cure at day 90 and 180, Microbiological cure *at day 30, 90 and 180, Incidence of relapse /recurrence between day 30 and day 90, Incidence of adverse events imputable to antibiotic treatment, Kidney function assessed according to MDRD (Modification of Diet in Renal Disease) or CKD (Chronic Kidney Disease - Epidemiology Collaboration) epi, Hospitalization length stay defined by the delay between the date of inclusion and the date of hospital discharge, Antibiotic consumption, Rectal carriage of antibiotic resistant Enterobacteriaceae at inclusion and day 30
Interventions
DRUG-
Sponsors
Assistance Publique Hopitaux De Paris, Assistance Publique Hopitaux De Paris
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical cure and no additional antibiotic treatment since the end of antibiotic treatment up to the main evaluation at day 30. Clinical cure is defined as fever <38°C and no symptoms of UTI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical cure at day 90 and 180, Microbiological cure *at day 30, 90 and 180, Incidence of relapse /recurrence between day 30 and day 90, Incidence of adverse events imputable to antibiotic treatment, Kidney function assessed according to MDRD (Modification of Diet in Renal Disease) or CKD (Chronic Kidney Disease - Epidemiology Collaboration) epi, Hospitalization length stay defined by the delay between the date of inclusion and the date of hospital discharge, Antibiotic consumption, Rectal carriage of antibiotic resistant Enterobacteriaceae at inclusion and day 30 | — |
Countries
France
Outcome results
None listed